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Objective: Chest pain is a common finding in patients with hypertrophic cardiomy-
opathy and can be observed in 40% to 50% of all patients. However, the patho-
genesis of these ischemia-like symptoms is still unclear.
Methods: Twenty-two patients with hypertrophic cardiomyopathy and 15 controls
underwent positron emission tomography for evaluation of regional myocardial
perfusion and coronary flow reserve (hyperemic/baseline myocardial blood flow).
Myocardial perfusion (mL/min/g) was measured using [13N]ammonia at rest and
during hyperemia with dipyridamole (0.56 mg/kg intravenously). Regional coronary
flow reserve was assessed in 3 planes (apical, midventricular, basal) in 4 regions
(septal, anterior, lateral, inferior). Patients were divided into 2 groups: group 1
consisted of 11 patients treated with surgical myectomy (age 56  10 years) and
group 2 consisted of 11 patients treated medically (age 53  13 years).
Results: Mean global coronary flow reserve was 3.87  0.92 in controls but 2.31 
0.40 in operated (P .001 vs controls) and 1.76 0.58 in medically treated patients
(P  .001 vs controls, P  .05 vs operated). Similarly, septal coronary flow reserve
was 4.19  1.22 in controls but significantly reduced in operated patients (2.26 
0.48, P .001 vs controls) and in medically treated patients (1.76 0.58; P .001
vs controls). However, septal flow reserve was significantly higher in operated
patients than in patients with medically treated hypertrophic cardiomyopathy
(37%, P  .05), mainly due to a reduced resting myocardial perfusion.
Conclusions: Global and regional myocardial perfusion is reduced in patients with
hypertrophic cardiomyopathy. However, myectomy may have a beneficial effect on
septal perfusion and flow reserve. Thus, ischemia seems to play an important role in
the symptomatology and pathophysiology of hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is a progressive disease withsignificant morbidity and mortality. Sudden unexpected death canbe the first clinical manifestation of HCM and is the most dev-astating feature in the natural history of the disease. Occurrence ofsudden cardiac death has been reported to be about 2% to 3% peryear.1 Approximately 60% to 70% of all patients with this disease
die suddenly. Hemodynamic and electrophysiological studies in patients with HCM
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have demonstrated several potential mechanisms for cardiac
arrest or sudden death, including atrial arrhythmias associ-
ated with hypotension, bradyarrhythmias, and ventricular
tachyarrhythmias, all of which can be exacerbated in the
presence of left ventricular outflow tract obstruction or
myocardial ischemia.2 Chest pain and signs of ischemia
have been found to occur frequently.3 In HCM, similarly to
severe secondary left ventricular hypertrophy, the metabolic
demands of the increased left ventricular muscle mass can-
not be met by a parallel increase in coronary luminal area.4
As a consequence of left ventricular hypertrophy, large
epicardial coronary arteries are dilated, which leads to a
reduced coronary vasodilator capacity5 and impaired flow
reserve, resulting in an underperfusion during high demand
conditions. The pathophysiology of myocardial perfusion in
the HCM muscle area may be crucial for sudden cardiac
death. Camici and coworkers6 reported an impaired coro-
nary vasodilator reserve in both hypertrophied and nonhy-
pertrophied regions of the left ventricle in HCM using
positron emission tomography (PET), suggesting that ische-
mia may result from abnormalities of the coronary micro-
circulation. This is supported by postmortem2 and ex vivo7
analyses of HCM hearts where an abnormal thickening of
the arteriolar wall and a decreased capillary density were
found with progressive left ventricular hypertrophy.
Surgical management of HCM was first introduced by
Cleland,8 who performed myotomy/myectomy of the hyper-
trophied septum using a transventricular approach. This
technique was later adapted by others, and transaortic my-
ectomy has become the treatment of choice for severely
symptomatic patients with large outflow tract pressure gra-
dients,9 which is a strong, independent predictor of progres-
sion to severe symptoms of heart failure and of death.10
Septal myectomy has been associated with an improvement
in symptoms and an increase in exercise capacity, but
whether it prevents septal ischemia by changing the perfu-
sion pattern, and thus prolongs life, remains unclear.
The aim of the present study was to evaluate the influ-
ence of surgical myectomy on regional and global perfusion
and to compare it to medically treated patients with HCM.
Methods
The study protocol was approved by the local ethics committee.
The investigation conforms with the principle outlines in the
Declaration of Helsinki. Each volunteer signed the informed con-
sent form after the investigative nature of the study and its risks
and merits had been carefully explained.
Study Population
A total of 22 patients with HCM were studied: 11 had undergone
surgical myectomy (HCM op) 13  5 years ago and 11 were
medically treated (HCM med). Mean age was 56  10 and 54 
13 years for operated patients and medically treated patients,
respectively (P  NS). All medication was withdrawn 48 hours
before the study. Six patients operated for HCM were treated with
the calcium channel blocker verapamil and 3 with beta-blockers,
whereas 3 of the medically treated patients were on each of these
treatment options. In the medically treated group angina pectoris
was present in 4, dyspnea in 5, and syncope in 3 patients. Dyspnea
was reported in 5 operated patients during the postoperative fol-
low-up. Prior to myectomy, however, all patients were symptom-
atic with either dyspnea (7 patients) or angina (7 patients) or
syncope (8 patients) or a combination of these. The policy for
conservative (medical) or surgical treatment remained unchanged
at our hospital over the years of the study and was as follows. (1)
Patients with a significant pressure gradient (25 but 50 mm
Hg) or typical symptoms that responded well to medical therapy
were followed on medical treatment. (2) Patients were treated
surgically if they had a resting pressure gradient of more than 50
mm Hg or a pressure gradient after postextrasystolic potentiation
of more than 100 mm Hg or when clinical symptoms were present
that did not respond or insufficiently responded to medical therapy.
The same operator performed surgical myectomy in all patients by
the transaortic/transventricular approach throughout the years.
None of the patients was treated by transcatheter alcohol ablation.
Fifteen volunteers without cardiovascular disease served as
controls (mean age of 34  14 years; P  .01 vs HCM). None of
the controls had a history of cardiovascular disease or risk factors.
Entrance criteria included normal heart rate, blood pressure, nor-
mal resting electrocardiogram (ECG), and low clinical probability
for coronary artery disease.11
The study was performed after overnight fasting. All subjects
were carefully instructed to refrain from caffeine intake within 24
hours before the study.
Study Protocol
All volunteers were injected with 700 to 900 MBq [13N]ammonia
into a peripheral vein by bolus technique while acquisition of the
serial transaxial tomographic images of the heart was started. The
20-minutes acquisition scan was followed by a 20-minute trans-
mission scan for photon attenuation correction using external 68Ge
sources. This was followed by an intravenous infusion of dipyrid-
amole (140 g/kg/min) over 4 minutes and a second bolus of 700
MBq [13N]ammonia, which was injected 8 minutes after starting of
the dipyridamole infusion.
PET Scanning
All images were acquired on a General Electric positron emission
tomograph, which records 35 image planes simultaneously. The
axial field of view is 14.5 cm. A 30-minute blank scan was
recorded as part of the daily routine procedures. Correct position-
ing of the volunteer’s heart within the axial field of view of the
tomograph was ascertained on a 4-minute rectilinear transmission
scan. Starting with the intravenous administration of [13N]ammo-
nia, 12 frames of 10 seconds each, 4 of 30 seconds, 1 of 60
seconds, and 2 of 300 seconds were recorded.
Data Analysis
The transaxially acquired images were reoriented to obtain short-
axis images of the heart. A basal, a midventricular, and an apical
slice were then chosen for further analysis. In each slice a region
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of interest (ROI) was placed within the septal, anterior, lateral, and
inferior segments.
Estimates of Myocardial Blood Flow
A spherical ROI was placed into the blood pool of the left ventri-
cle. Myocardial and blood pool time-activity curves were gener-
ated from the dynamic frames and corrected for radioisotope
decay. Myocardial blood flow (MBF) was estimated by model
fitting of the blood pool and myocardial time-activity curves using
a 3-compartment model.12
The corrections for partial volume and spillover (both account-
ing for the resolution distortion) have been performed using the
method described and validated by Hutchins and coworkers.13
Briefly, the ROI is chosen to contain only myocardial tissue and
blood and, thus, the relation between the measured PET counts in
a region (CPET) and the true counts in myocardium (Cm) and
arterial blood (Ca) is modeled as follows: CPET(t)  FaCa(t)
 (1  Fa)Cm(t). Fa is the fractional contribution of the blood
pool to measured PET counts in a region and is dependent on the
placement of the region, the resolution of the camera, and move-
ment of the myocardium. Because the contribution of myocardium
to total regional counts decreases with increasing blood pool
fraction, cm is multiplied with (1  Fa). Fa is estimated together
with the other kinetic tissue parameters using least-squares fitting.
Coronary flow reserve (CFR) was calculated as the ratio of
hyperemic to resting MBF for global and regional MBF values. To
account for the variability of coronary driving pressure, coronary
resistance (mm Hg/mL/min/g) was also calculated as the ratio of
mean arterial pressure to MBF as previously reported.14
Statistical Analysis
Statistical comparison of hemodynamic data, MBF, and CFR were
carried out by a 1-way analysis of variance for repeated measure-
ments. When the analysis was significant, the Scheffe´ procedure
was applied. Data are reported as mean values  standard devia-
tion (SD) if not otherwise stated.
Results
All procedures were well tolerated apart from the common
side effects caused by dipyridamole. None of the subjects
experienced any ECG changes during the procedure.
Echocardiographic Data
In the operated patients preoperative gradients were 63 
15 mm Hg. The postoperative data (Table 1) show that in
operated patients compared with medically treated patients
there was a tendency to smaller interventricular septal wall
thickness and lower fractional shortening and pressure gra-
dient, which fell short of statistical significance. Left ven-
tricular end-diastolic chamber diameter did not differ be-
tween the 2 groups (Table 1). Six of the medically treated
patients had no outflow tract obstruction and 5 had a gra-
dient of 26  17 mm Hg (63  16 mm Hg during Valsalva
maneuver).
Hemodynamics
Heart rate, systolic and diastolic pressure, as well as rate
pressure product (RPP) were comparable in the 3 groups.
Under dipyridamole infusion RPP increased significantly
after dipyridamole in controls (11520  2124 vs 7424 
815, P  .01), in patients who had undergone surgical
myectomy (9840  2450 vs 7720  850, P  .01) and in
medically treated patients (10671  1483 vs 8083  1678,
P  .01). There was no significant difference between RPP
of the 3 groups after dipyridamole.
MBF and CFR
Global MBF at baseline was similar in controls (0.72 
0.20 mL/g/min) and operated patients (0.67  0.15 mL/g/
min) but higher in medically treated patients (0.89  0.21
mL/g/min, P  .01 vs both). Dipyridamole induced a sig-
nificant increase in MBF in controls (3.04  1.00 mL/g/
min, P  .0001 vs baseline) and in patients with hypertro-
phic cardiomyopathy (P  .005). However, the response
was significantly reduced in operated patients (1.55  0.39
mL/g/min) and medically treated patients (1.49  0.47
mL/g/min, both P  .001 vs controls; Figure 1). This
resulted in a global CFR of 3.87 0.92 for controls, 2.31
0.40 for operated patients (P  .001 vs controls), and 1.76
 0.58 for medically treated patients (P  .001 vs controls,
P  .05 vs operated patients), respectively (Table 2).
Septal MBF was 0.90  0.27 mL/g/min in controls, 0.68
 0.14 mL/g/min in operated patients (P .05 vs controls),
and 0.87  0.18 mL/g/min in medically treated patients (P
 .05 vs operated patients). Hyperemic MBF was signifi-
cantly larger in controls (3.78  1.67) than operated pa-
tients (1.54  0.33, P  .001 vs controls) or medically
treated patients (1.40 0.45, P .001 vs controls), respec-
tively (Figure 1). Septal CFR was 4.19  1.22 in controls,
but significantly reduced in operated patients (2.26  0.48,
TABLE 1. Echocardiographic data
HCM op HCM med P
IVS (mm) 19 8 24 5 NS
PW (mm) 13 3 12 3 NS
LVEDD (mm) 47 4 45 5 NS
FS (%) 37 8 45 9 NS
SAM (yes/no) 3/8 4/7 NS
P (mm Hg) 8 16 20 32 NS
HR 66 9 74 10 NS
SBP 120 15 120 8 NS
DBP 70 10 74 10 NS
RPP 7982 1456 8175 1731 NS
IVS, Interventricular septum; PW, posterior wall; LVEDD, left ventricular
end-diastolic diameter; FS, fractional shortening; SAM, systolic anterior
motion of the anterior mitral leaflet; P, pressure gradient; HR, heart rate;
SBP, systolic blood pressure; DBP, diastolic blood pressure; RPP, rate
pressure product; NS, not significant.
Jo¨rg-Ciopor et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 128, Number 2 165
CS
P
P .001 vs controls) and medically treated patients (1.65
0.53; P .001 vs controls). CFR was significantly higher in
operated than medically treated patients (37%, P  .05).
Furthermore, the difference in CFR between the lateral free
wall and the septum was larger in medically treated patients,
namely 16% (P  .05 vs controls) compared with 7% in
operated patients and 5% in controls (Figure 2).
Influence of Outflow Tract Gradient on Maximal
MBF, CFR, and Coronary Resistance
In the medically treated group patients with outflow tract
obstruction, maximal hyperemic MBF was significantly
lower in septal (1.1 0.3 mL/min/g vs 1.7 0.4 mL/min/g;
P  .05) and lateral segments (1.3  0.3 mL/min/g vs 2.0
 0.6 mL/min/g; P  .05) compared with patients without
outflow tract obstruction. Accordingly, in comparison with
nonoperated patients gradient maximal hyperemic blood
flow was significantly improved after myectomy in septal
(1.6  0.3 mL/min/g vs 1.2  0.3 mL/min/g, P  .05) and
lateral (1.8 0.4 mL/min/g vs 1.4 .3 mL/min/g, P .05)
segments as was global CFR (Figure 3).
After myectomy minimal septal coronary resistance was
significantly lower compared with nonoperated patients
with outflow tract obstruction (57  10 mm Hg/mL/min/g
vs 79  21 mm Hg/mL/min/g, P  .05), reaching values
comparable to those found in patients without gradient (52
 5 mm Hg/mL/min/g). In controls minimal coronary re-
sistance was significantly lower compared with either group
of patients with HCM (34  14 mm Hg/mL/min/g; P 
.01).
Figure 1. Septal and global MBF. Septal and global myocardial
blood flow (MBF) are given at rest and during dipyridamole-
induced hyperemia (stress) for controls, operated patients (HCM
op), as well as medically treated patients with hypertrophic
cardiomyopathy (HCM med). Global as well as septal hyperemic
response are largely blunted in HCM.
Figure 2. Difference between lateral and septal CFR. Controls and
operated patients with hypertrophic cardiomyopathy (HCM op)
have only modest regional difference between septal and lateral
coronary flow reserve (CFR). By contrast, in medically treated
patients with hypertrophic cardiomyopathy (HCM med) this dif-
ference is significantly larger.
Figure 3. Influence of outflow tract gradient on vasodilatory re-
sponse. Hyperemic MBF and CFR were significantly lower and
minimal resistance significantly higher in medically treated pa-
tients with hypertrophic cardiomyopathy (HCM med) with gradi-
ent compared with HCM med without gradient as well as com-
pared with operated patients with hypertrophic cardiomyopathy
(HCM op). **P < .01 vs HCM med with gradient.
Cardiopulmonary Support and Physiology Jo¨rg-Ciopor et al
166 The Journal of Thoracic and Cardiovascular Surgery ● August 2004
CSP
Discussion
The results of the present study confirm and extend previous
observations of reduced CFR in HCM. In moderately symp-
tomatic patients with HCM but without evidence for coro-
nary artery disease we found a decreased CFR in agreement
with earlier reports.3,6,7 Similarly to Camici and cowork-
ers,6 CFR after dipyridamole stress was impaired in both
hypertrophic and nonhypertrophic regions (ie, lateral free
wall). This suggests a primary abnormality of the coronary
bed as a cause for the blunted coronary flow response.
Additionally, we found a relative reduction of septal CFR
compared with the lateral wall in medically treated patients
with HCM, supporting results from Grover-McKay and
colleagues,15 who found significantly reduced [13N]-ammo-
nia concentrations in the septum compared with the lateral
wall of the left ventricle in HCM, while the opposite pattern
is commonly found in normal volunteers.16 Our study is the
first to investigate the impact of myectomy on regional
myocardial perfusion. After surgical myectomy the ob-
served difference between septal and lateral CFR was abol-
ished despite the globally higher CFR in operated patients
with HCM (Figure 2). Septal CFR was significantly higher
in operated patients than in medically treated patients, al-
though CFR in both groups remained significantly reduced
compared with controls.
Determinants of CFR
CFR, defined as the ratio of near maximal to basal MBF, has
been proposed as an indirect parameter to evaluate the
function of the coronary circulation. It is an integrated
measure of coronary flow through both the large epicardial
coronary arteries and the microcirculation. A decrease in
CFR can be due to the narrowing of epicardial coronary
arteries—which was excluded in the present study, howev-
er—or to microvascular dysfunction.17 The latter can the-
oretically be caused by several mechanisms: (1) structural
changes (ie, vascular remodeling with reduced lumen to
wall ratio) or functional alterations involving neurohumoral
factors; (2) small coronary arterioles may change their di-
ameter as a result of autonomic innervation18; (3) several
extravascular mechanisms such as impaired diastolic relax-
ation, compression of the coronary arteries by high left
ventricular filling pressures, and increased force of contrac-
tion (“milking”).
Mechanisms of Impaired CFR in HCM: Role of
Myectomy
Although the precise mechanism of myocardial ischemia in
individual patients with HCM is not clear, a number of
pathophysiologic features have been found to cause a mis-
match between oxygen supply and demand, including in-
creased myocardial muscle mass, reduced capillary densi-
ty,7 and “small vessel disease.”7,15 Recently, Schafers and
coworkers19 documented presynaptic and postsynaptic au-
tonomic dysfunction in HCM, with increased local cate-
cholamine levels and down-regulation of myocardial beta-
adrenergic receptors, which could contribute to
microcirculatory dysregulation. Left ventricular diastolic
dysfunction in HCM has the potential to cause myocardial
ischemia probably by causing a maldistribution of
transmyocardial blood flow, with a reduced subendocardial/
subepicardial flow ratio after dipyridamole infusion.20 An
outflow tract obstruction is associated with reduced maxi-
mal hyperemic flow. Myectomy may exert its beneficial
effect on CFR by reducing extravascular compressive forces
as a result of improved diastolic relaxation, reduced force of
contraction, and, thus, reduced compression of the coronary
arteries. These mechanisms may not be entirely limited to
the septum and therefore may have some influence on
global CFR, as evidenced by the higher global CFR in
operated patients compared with medically treated patients
without outflow tract obstruction.
CFR is defined as ratio of hyperemic to resting MBF and
therefore may be susceptible to changes in the denominator
(ie, the resting flow). Resting MBF was significantly lower
in operated patients than medically treated HCM patients.
However, the absolute hyperemic flow data (Table 2) fur-
ther substantiate the CFR data, as operated patients had
significantly higher hyperemic MBF compared with medi-
cally treated patients with obstruction.
TABLE 2. MBF and CFR measurements
Controls HCM-op HCM-med
sep lat glob sep lat glob sep lat glob
MBF—rest 0.90 0.27 0.75 0.28 0.72 0.20 0.68 0.14† 0.70 0.16 0.67 0.15 0.87 0.18* 0.89 0.20* 0.89 0.21†*
MBF—stress 3.78 1.67 2.70 0.82 3.04 1.00 1.54 0.33§ 1.70 0.42‡ 1.55 0.39§ 1.40 0.45§ 1.63 0.60‡ 1.49 0.47§
CFR 4.19 1.22 3.81 1.06 3.87 0.92 2.26 0.48§ 2.42 0.49‡ 2.31 0.40§ 1.65 0.53§* 1.89 0.70§ 1.76 0.58§
Stress, Pharmacologic stress with intravenous dipyridamole (0.56 mg/kg); sep, septal; lat, lateral; glob, global.
Values of MBF are given as mL/min/g; values of CFR are relative values.
*P  .05 vs controls.
†P  .01 vs controls.
‡P  .001 vs controls.
§P  .05 vs patients surgically treated for hypertrophic cardiomyopathy.
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Accordingly, septal coronary resistance, which was cal-
culated to account for the driving pressure, was significantly
higher in medically treated patients with outflow tract ob-
struction compared with those without obstruction and was
significantly reduced after myectomy. This is illustrated
best in Figure 2, showing that the difference in CFR be-
tween the lateral free wall and septum is maximal in sub-
jects with gradient. Thus, our data confirm that myectomy
improved vasodilator response in HCM, most probably due
to the removal of the obstruction, although it cannot be ruled
out that the 2 groups of patients with HCM did not start off
at the same point in the disease process. It is, however,
unlikely that the differences in MBF and CFR between
operated patients and medically treated patients were al-
ready present before myectomy as the gradient seems to
play the major role. Only measurements before and after
myectomy in the same patients would provide definitive
answers.
The beneficial effect of myectomy on CFR adds evi-
dence that ischemia may indeed play an important role in
the symptomatology and pathophysiology of HCM. The
significantly reduced maximal MBF and CFR in patients
with HCM suggests that ischemia may occur during high
coronary flow and oxygen demand situations such as mental
stress or physical activity. This is supported by the clinical
finding that chest pain was less common in operated patients
with HCM (none of the patients) than in medically treated
patients with HCM (4 patients; chi-square test: P .05) and
is in line with results of Cannon and coworkers,21 who
reported a net lactate release in the coronary sinus during
atrial pacing as a biochemical substrate for the simulta-
neously documented reversible defects in thallium-201
scanning.
Study Limitations
The large differences in wall thickness between patients
with HCM and controls may affect the correct interpretation
of the flow data due to differences in partial volume effects.
To minimize these effects, we have corrected for partial
volume effects by applying the method proposed by
Hutchins and coworkers.13 The partial volume effect is
extremely important in thin walls of less than 5 mm but less
problematic in hypertrophic hearts with thick walls.13
Patients with HCM were significantly older than the
controls. This may have affected our results. In fact, Czernin
et al22 found a gradual decline in CFR with aging. This was,
however, primarily due to increased cardiac work and blood
flow at rest rather than to an abnormal vasodilator capacity
(since dipyridamole-induced hyperemic flow was not af-
fected by aging). This does clearly not apply to our study,
where baseline MBF was lower in patients with HCM
despite their higher age. In addition, Uren and coworkers23
reported that MBF at rest and during hyperemia (and thus
CFR) are roughly comparable up to 60 years of age. In the
age group of 50 to 59 years, CFR tended to be maximal and
even slightly higher than in the age group of 30 to 39 years
(ie, our control group’s age). Thus, CFR would be expected
to be higher in both HCM groups, rather than lower, com-
pared with the younger controls, a fact that strengthens even
further our results.
Differences in medical treatment between operated and
medically treated HCM may represent a confounding factor
for direct comparison of these groups. Indeed, 6 patients
operated for HCM were treated with the calcium channel
blocker verapamil, whereas only 3 of the medically treated
patients were on this treatment. However, although vera-
pamil has beneficial effects on the left ventricular relax-
ation24 and on transmural MBF distribution in HCM,25 it
has no effect on total MBF as assessed with PET.26
Conclusions
Global as well as septal CFR is reduced in patients with
HCM. However, myectomy seems to have a beneficial
effect on septal perfusion and CFR. Thus, ischemia may
play an important role in the symptomatology and patho-
physiology in HCM.
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